• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: Researchers develop ingestible capsule for insulin delivery

February 11, 2019 By Sarah Faulkner

Image Credit: Felice Frankel

A team of researchers from MIT developed an ingestible, blueberry-sized capsule that can deliver insulin orally. In animal models, the capsule lowered blood sugar levels and performed comparably with the traditional route of insulin delivery – injections.

The capsule features a small needle made of freeze-dried, compressed insulin. The needle is attached to a compressed spring, which is held in place by a sugar disk. Once the capsule reaches the stomach, the sugar disk dissolves and the needle injects into the stomach wall.

When the needle tip injects into the stomach wall, the insulin dissolves at a controllable rate. In animal testing published in Science, it took roughly an hour for the entire dose of insulin to be released into the pig’s bloodstream.

“We are really hopeful that this new type of capsule could someday help diabetic patients and perhaps anyone who requires therapies that can now only be given by injection or infusion,” senior author Robert Langer told MIT News.

Inspired by the shell of a tortoise, the researchers designed the capsule with a self-orientation feature that allows the pill to orient the needle with the stomach lining no matter how it lands in the stomach.

“As soon as you take it, you want the system to self-right so that you can ensure contact with the tissue,” senior author Giovanni Traverso explained.

“What’s important is that we have the needle in contact with the tissue when it is injected,” graduate student Alex Abramson added. “Also, if a person were to move around or the stomach were to growl, the device would not move from its preferred orientation.”

According to MIT News, the team of researchers is working with Novo Nordisk (NYSE:NVO) to advance the capsule technology and work out the manufacturing process. Novo Nordisk, along with the NIH and Brigham & Women’s Hospital, helped to fund the project.

“Our motivation is to make it easier for patients to take medication, particularly medications that require an injection,” Traverso said. “The classic one is insulin, but there are many others.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development Tagged With: Brigham & Women's Hospital, Massachusetts Institute of Technology, National Institutes of Health, Novo Nordisk

IN CASE YOU MISSED IT

  • 8 drug delivery innovations you need to know
  • Axonics acquires Contura and its Bulkamid bulking agent for $235M
  • Lilly to add Welldoc app to future insulin pen
  • Kala Pharmaceuticals slides on missed Q4 projections
  • Semaglutide paired with behavioral therapy tripled weight loss in trial

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS